Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promo...
Saved in:
Published in | Frontiers in pharmacology Vol. 13; p. 843110 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
17.02.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy.
Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival.
Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1-2.
Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-naïve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment. |
---|---|
AbstractList | Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy.Methods: Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival.Results: Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1–2.Conclusion: Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-naïve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment. To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy. Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival. Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1-2. Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-naïve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment. Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy. Methods: Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival. Results: Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1–2. Conclusion: Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-naïve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment. Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therapy, to promote the consensus on the optimal regimen for achieving superior treatment efficacy. Methods: Through literature search in PubMed, articles with the following relevant keywords were collected and anlyzed: CRPC, abiraterone, orteronel and enzalutamide, median survival, overall survival, prostate specific antigen (PSA), PSA response rate and median radiologic progression-free survival. Results: Fifty-eight articles were obtained and analyzed in this review. These articles included androgen axis-targeting agents after docetaxel, docetaxel after androgen axis-targeting agents, Triple sequential and combination therapy, covering four current drugs for mCRPC treatment: docetaxel, abiraterone, orteronel, and enzalutamide. It was found that there may be some cross-resistance between androgen axis-targeting agents, which will reduce the efficacy of subsequent drug treatment. Although neither of the studies of using combination therapy showed serious drug toxicity, the efficacy of sequential therapy was not as good as expected. Most adverse reactions after treatment were reported to be level 1–2. Conclusion: Based on the results of the current studies, abiraterone followed by enzalutamide treatment is the best sequential treatment for most docetaxel-naïve patients. This treatment achieves not only good OS, but also PFS and PSA response rates. In addition, for patients who have previously failed docetaxel treatment, enzalutamide is the best choice as the subsequent treatment. |
Author | Zhao, Shan-Chao Chen, Ming-Kun Chen, Zhe-Sheng Liao, De-Ying Luo, Dao-Sheng Yu, Yuzhong Liang, Zhi-Jian Xue, Kang-Yi Li, Zheshen |
AuthorAffiliation | 5 Department of Urology , Nanfang Hospital , Southern Medical University , Guangzhou , China 3 Dongguan Hospital , Southern Medical University , Dongguan , China 4 Department of Pharmaceutical Sciences , College of Pharmacy and Health Sciences , St. John’s University , Queens , NY , United States 2 Department of Urology, The Third Clinical College of Southern Medical University , Guangzhou , China 1 Department of Urology , The Third Affiliated Hospital , Southern Medical University , Guangzhou , China |
AuthorAffiliation_xml | – name: 3 Dongguan Hospital , Southern Medical University , Dongguan , China – name: 5 Department of Urology , Nanfang Hospital , Southern Medical University , Guangzhou , China – name: 1 Department of Urology , The Third Affiliated Hospital , Southern Medical University , Guangzhou , China – name: 4 Department of Pharmaceutical Sciences , College of Pharmacy and Health Sciences , St. John’s University , Queens , NY , United States – name: 2 Department of Urology, The Third Clinical College of Southern Medical University , Guangzhou , China |
Author_xml | – sequence: 1 givenname: Ming-Kun surname: Chen fullname: Chen, Ming-Kun organization: Department of Urology, The Third Clinical College of Southern Medical University, Guangzhou, China – sequence: 2 givenname: Zhi-Jian surname: Liang fullname: Liang, Zhi-Jian organization: Department of Urology, The Third Clinical College of Southern Medical University, Guangzhou, China – sequence: 3 givenname: Dao-Sheng surname: Luo fullname: Luo, Dao-Sheng organization: Dongguan Hospital, Southern Medical University, Dongguan, China – sequence: 4 givenname: Kang-Yi surname: Xue fullname: Xue, Kang-Yi organization: Department of Urology, The Third Clinical College of Southern Medical University, Guangzhou, China – sequence: 5 givenname: De-Ying surname: Liao fullname: Liao, De-Ying organization: Department of Urology, The Third Clinical College of Southern Medical University, Guangzhou, China – sequence: 6 givenname: Zheshen surname: Li fullname: Li, Zheshen organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States – sequence: 7 givenname: Yuzhong surname: Yu fullname: Yu, Yuzhong organization: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China – sequence: 8 givenname: Zhe-Sheng surname: Chen fullname: Chen, Zhe-Sheng organization: Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States – sequence: 9 givenname: Shan-Chao surname: Zhao fullname: Zhao, Shan-Chao organization: Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35250590$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUtP3DAQx60KVJ4foJcqxx7Yrd9r91CEFtoiIXGAnq1JPGaNknjrZKvCp8dLKIK5eDSP34znf0B2-tQjIZ8YnQth7NewXkGec8r53EjBGP1A9pnWYmYN4ztv_D1yPAz3tJiwVmj5kewJxRVVlu6Tm7M6ZhgxF_hJdZ0nrz2pLvpHaDcjdNFjBb2vzlODI_zD9lt1g3822I8R2irlapm6Ovboq9sVZlg_nB6R3QDtgMcv7yH5_ePidvlrdnX983J5djVrpFbjzMjaBh0kaJDagoWAyIQUPvjGeq1rHxhXGqzgDUBdMkpJBFB-wQwtgUNyOXF9gnu3zrGD_OASRPccSPnOQR5j06IDW0uBZRBqlEYH0AoX2lJLDa95sIX1fWKtN3WHvinfy9C-g77P9HHl7tJfZ4xlytAC-PICyKlcZxhdF4cG2xZ6TJvBcS20MQvOt6VsKm1yGoaM4XUMo26rrXvW1m21dZO2pefz2_1eO_4rKZ4AJYWjsA |
CitedBy_id | crossref_primary_10_1038_s41598_024_51360_9 crossref_primary_10_3390_cancers16101933 crossref_primary_10_3389_fonc_2023_1240864 crossref_primary_10_1002_cpz1_1033 crossref_primary_10_3389_fimmu_2022_869759 |
Cites_doi | 10.1056/NEJMoa040720 10.1016/s1470-2045(19)30688-6 10.1093/annonc/mdt136 10.1016/s1470-2045(19)30684-9 10.1002/cncr.28518 10.1016/j.jsbmb.2012.01.001 10.1016/j.euo.2019.01.008 10.1126/science.1168175 10.1159/000365530 10.1021/jm00013a022 10.1155/2017/8560827 10.1016/s1470-2045(15)70033-1 10.1007/s12325-014-0092-1 10.1200/jco.2010.33.7675 10.21873/anticanres.13541 10.1124/pr.58.4.9 10.1111/iju.13346 10.1093/annonc/mdv129 10.1158/1541-7786.MCR-14-0036 10.1111/j.1464-410X.2011.10277.x 10.3322/caac.2155110.3322/caac.21565 10.1158/0008-5472.Can-11-3980 10.1016/j.eururo.2014.06.045 10.1056/NEJMoa1014618 10.1200/jco.2019.37.7_suppl.202 10.3390/cancers12010008 10.1200/jco.2018.77.9827 10.1002/pros.22872 10.1038/pcan.2014.53 10.1056/NEJMoa041318 10.3109/21681805.2013.860189 10.1158/1078-0432.Ccr-12-2910 10.3390/jcm8081251 10.3389/fphar.2017.00055 10.1016/j.eururo.2014.05.005 10.1016/j.bmc.2011.08.066 10.1007/s12032-017-1060-9 10.1126/science.93.2421.489 10.1002/pros.23236 10.1002/pros.23309 10.1200/jco.2005.03.4777 10.4103/aja.aja_85_18 10.1056/NEJMoa1405095 10.1093/annonc/mdt138 10.1056/NEJMoa1207506 10.1016/j.ejca.2013.08.020 10.1056/NEJMoa1209096 10.1016/j.eururo.2014.01.018 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao. Copyright © 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao. 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao |
Copyright_xml | – notice: Copyright © 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao. – notice: Copyright © 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao. 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fphar.2022.843110 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Chen et al |
EISSN | 1663-9812 |
EndPage | 843110 |
ExternalDocumentID | oai_doaj_org_article_a9b43e6a4e6e486fa65e76909082b2f9 10_3389_fphar_2022_843110 35250590 |
Genre | Journal Article Review |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV DIK EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW IPNFZ KQ8 M48 M~E NPM O5R O5S OK1 P2P PGMZT RIG RNS RPM AAYXX CITATION 7X8 ITC 5PM |
ID | FETCH-LOGICAL-c465t-84b9f6f4a6a469a9afee1343dfdc9d66bdf1256a932caab343554eaa5d7180ab3 |
IEDL.DBID | RPM |
ISSN | 1663-9812 |
IngestDate | Fri Oct 04 13:13:47 EDT 2024 Tue Sep 17 21:23:14 EDT 2024 Sat Aug 17 02:55:12 EDT 2024 Thu Sep 26 16:51:32 EDT 2024 Sat Sep 28 08:20:44 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | combined therapy sequential therapy abiraterone docetaxel metastatic castration-resistant prostate cancer orteronel enzalutamide |
Language | English |
License | Copyright © 2022 Chen, Liang, Luo, Xue, Liao, Li, Yu, Chen and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-84b9f6f4a6a469a9afee1343dfdc9d66bdf1256a932caab343554eaa5d7180ab3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Reviewed by: Zhi-hang Zhou, Chongqing Medical University, China These authors have contributed equally to this work This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Lingzhi Li, University of Texas MD Anderson Cancer Center, United States Edited by: Benyi Li, University of Kansas Medical Center, United States |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891580/ |
PMID | 35250590 |
PQID | 2636887220 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_a9b43e6a4e6e486fa65e76909082b2f9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8891580 proquest_miscellaneous_2636887220 crossref_primary_10_3389_fphar_2022_843110 pubmed_primary_35250590 |
PublicationCentury | 2000 |
PublicationDate | 2022-02-17 |
PublicationDateYYYYMMDD | 2022-02-17 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-17 day: 17 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Frontiers in pharmacology |
PublicationTitleAlternate | Front Pharmacol |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Bastos (B6) 2014; 28 Efstathiou (B16) 2012; 30 Lin (B27) 2019; 21 Scher (B40) 2005; 23 Chung (B14) 2019; 12 Cathomas (B10) 2016; 76 Caffo (B9) 2011; 108 Esch (B19) 2014; 37 Huggins (B22) 1941; 93 Lorente (B28) 2015; 16 Chopra (B13) 2017; 77 Chang (B11) 2019; 39 Schweizer (B42) 2014; 66 Attard (B2) 2018; 36 Miller (B32) 2019; 69 Azad (B3) 2015; 67 Bianchini (B8) 2014; 50 Cheng (B12) 2015; 18 Scher (B39) 2012; 367 Miyake (B33) 2017; 34 Ryan (B38) 2013; 368 Al-Batran (B1) 2015; 26 Fang (B20) 2017; 2017 Noonan (B34) 2013; 24 Efstathiou (B18) 2020; 3 Thomsen (B46) 2014; 48 Hoffman-Censits (B21) 2013; 19 Kaku (B23) 2011; 19 Potter (B36) 1995; 38 Tannock (B44) 2004; 351 Loriot (B29) 2013; 24 Efstathiou (B17) 2015; 67 Richards (B37) 2012; 72 de Bono (B15) 2011; 364 Azad (B4) 2014; 74 Li (B26) 2017; 8 Mateo (B31) 2020; 21 Schmid (B41) 2014; 31 Terada (B45) 2017; 24 Badrising (B5) 2014; 120 Khalaf (B24) 2019; 20 Smith (B43) 2019; 37 Tran (B47) 2009; 324 Lu (B30) 2006; 58 Komura (B25) 2019; 8 Petrylak (B35) 2004; 351 Yamaoka (B48) 2012; 129 Beer (B7) 2014; 371 |
References_xml | – volume: 351 start-page: 1502 year: 2004 ident: B44 article-title: Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040720 contributor: fullname: Tannock – volume: 20 start-page: 1730 year: 2019 ident: B24 article-title: Optimal Sequencing of Enzalutamide and Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: a Multicentre, Randomised, Open-Label, Phase 2, Crossover Trial publication-title: Lancet Oncol. doi: 10.1016/s1470-2045(19)30688-6 contributor: fullname: Khalaf – volume: 24 start-page: 1807 year: 2013 ident: B29 article-title: Antitumour Activity of Abiraterone Acetate against Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and Enzalutamide (MDV3100) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt136 contributor: fullname: Loriot – volume: 21 start-page: 162 year: 2020 ident: B31 article-title: Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Gene Aberrations (TOPARP-B): a Multicentre, Open-Label, Randomised, Phase 2 Trial publication-title: Lancet Oncol. doi: 10.1016/s1470-2045(19)30684-9 contributor: fullname: Mateo – volume: 120 start-page: 968 year: 2014 ident: B5 article-title: Clinical Activity and Tolerability of Enzalutamide (MDV3100) in Patients with Metastatic, Castration-Resistant Prostate Cancer Who Progress after Docetaxel and Abiraterone Treatment publication-title: Cancer doi: 10.1002/cncr.28518 contributor: fullname: Badrising – volume: 129 start-page: 115 year: 2012 ident: B48 article-title: Orteronel (TAK-700), a Novel Non-steroidal 17,20-lyase Inhibitor: Effects on Steroid Synthesis in Human and Monkey Adrenal Cells and Serum Steroid Levels in Cynomolgus Monkeys publication-title: J. Steroid Biochem. Mol. Biol. doi: 10.1016/j.jsbmb.2012.01.001 contributor: fullname: Yamaoka – volume: 3 start-page: 119 year: 2020 ident: B18 article-title: Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients publication-title: Eur. Urol. Oncol. doi: 10.1016/j.euo.2019.01.008 contributor: fullname: Efstathiou – volume: 324 start-page: 787 year: 2009 ident: B47 article-title: Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer publication-title: Science doi: 10.1126/science.1168175 contributor: fullname: Tran – volume: 37 start-page: 492 year: 2014 ident: B19 article-title: Sequential Treatment with Taxanes and Novel Anti-androgenic Compounds in Castration-Resistant Prostate Cancer publication-title: Oncol. Res. Treat. doi: 10.1159/000365530 contributor: fullname: Esch – volume: 38 start-page: 2463 year: 1995 ident: B36 article-title: Novel Steroidal Inhibitors of Human Cytochrome P45017 Alpha (17 Alpha-Hydroxylase-C17,20-Lyase): Potential Agents for the Treatment of Prostatic Cancer publication-title: J. Med. Chem. doi: 10.1021/jm00013a022 contributor: fullname: Potter – volume: 2017 start-page: 8560827 year: 2017 ident: B20 article-title: Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis publication-title: Prostate Cancer doi: 10.1155/2017/8560827 contributor: fullname: Fang – volume: 16 start-page: e279 year: 2015 ident: B28 article-title: Sequencing of Agents in Castration-Resistant Prostate Cancer publication-title: Lancet Oncol. doi: 10.1016/s1470-2045(15)70033-1 contributor: fullname: Lorente – volume: 31 start-page: 234 year: 2014 ident: B41 article-title: Enzalutamide after Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer publication-title: Adv. Ther. doi: 10.1007/s12325-014-0092-1 contributor: fullname: Schmid – volume: 30 start-page: 637 year: 2012 ident: B16 article-title: Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.33.7675 contributor: fullname: Efstathiou – volume: 39 start-page: 3901 year: 2019 ident: B11 article-title: Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-Resistant Prostate Cancer: Single Center Experience publication-title: Anticancer Res. doi: 10.21873/anticanres.13541 contributor: fullname: Chang – volume: 58 start-page: 782 year: 2006 ident: B30 article-title: International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors publication-title: Pharmacol. Rev. doi: 10.1124/pr.58.4.9 contributor: fullname: Lu – volume: 24 start-page: 441 year: 2017 ident: B45 article-title: Exploring the Optimal Sequence of Abiraterone and Enzalutamide in Patients with Chemotherapy-Naïve Castration-Resistant Prostate Cancer: The Kyoto-Baltimore Collaboration publication-title: Int. J. Urol. doi: 10.1111/iju.13346 contributor: fullname: Terada – volume: 26 start-page: 1244 year: 2015 ident: B1 article-title: The Impact of Docetaxel-Related Toxicities on Health-Related Quality of Life in Patients with Metastatic Cancer (QoliTax) publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv129 contributor: fullname: Al-Batran – volume: 28 start-page: 693 year: 2014 ident: B6 article-title: Expanding Androgen- and Androgen Receptor Signaling-Directed Therapies for Castration-Resistant Prostate Cancer publication-title: Oncology (Williston Park) doi: 10.1158/1541-7786.MCR-14-0036 contributor: fullname: Bastos – volume: 108 start-page: 1825 year: 2011 ident: B9 article-title: Impact of Docetaxel-Based Chemotherapy on Quality of Life of Patients with Castration-Resistant Prostate Cancer: Results from a Prospective Phase II Randomized Trial publication-title: BJU Int. doi: 10.1111/j.1464-410X.2011.10277.x contributor: fullname: Caffo – volume: 69 start-page: 363 year: 2019 ident: B32 article-title: Cancer Treatment and Survivorship Statistics, 2019 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.2155110.3322/caac.21565 contributor: fullname: Miller – volume: 72 start-page: 2176 year: 2012 ident: B37 article-title: Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: a Rationale for Increasing Abiraterone Exposure or Combining with MDV3100 publication-title: Cancer Res. doi: 10.1158/0008-5472.Can-11-3980 contributor: fullname: Richards – volume: 67 start-page: 23 year: 2015 ident: B3 article-title: Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.06.045 contributor: fullname: Azad – volume: 364 start-page: 1995 year: 2011 ident: B15 article-title: Abiraterone and Increased Survival in Metastatic Prostate Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1014618 contributor: fullname: de Bono – volume: 37 start-page: 202 year: 2019 ident: B43 article-title: Phase II Study of Niraparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Biallelic DNA-Repair Gene Defects (DRD): Preliminary Results of GALAHAD publication-title: J. Clin. Oncol. doi: 10.1200/jco.2019.37.7_suppl.202 contributor: fullname: Smith – volume: 12 year: 2019 ident: B14 article-title: Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis publication-title: Cancers (Basel) doi: 10.3390/cancers12010008 contributor: fullname: Chung – volume: 36 start-page: 2639 year: 2018 ident: B2 article-title: Abiraterone Alone or in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer with Rising Prostate-specific Antigen during Enzalutamide Treatment publication-title: J. Clin. Oncol. doi: 10.1200/jco.2018.77.9827 contributor: fullname: Attard – volume: 74 start-page: 1544 year: 2014 ident: B4 article-title: A Retrospective, Canadian Multi-center Study Examining the Impact of Prior Response to Abiraterone Acetate on Efficacy of Docetaxel in Metastatic Castration-Resistant Prostate Cancer publication-title: Prostate doi: 10.1002/pros.22872 contributor: fullname: Azad – volume: 18 start-page: 122 year: 2015 ident: B12 article-title: Activity of Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Is Affected by Prior Treatment with Abiraterone And/or Docetaxel publication-title: Prostate Cancer Prostatic Dis. doi: 10.1038/pcan.2014.53 contributor: fullname: Cheng – volume: 351 start-page: 1513 year: 2004 ident: B35 article-title: Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa041318 contributor: fullname: Petrylak – volume: 48 start-page: 268 year: 2014 ident: B46 article-title: Enzalutamide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Chemotherapy and Abiraterone Acetate publication-title: Scand. J. Urol. doi: 10.3109/21681805.2013.860189 contributor: fullname: Thomsen – volume: 19 start-page: 1335 year: 2013 ident: B21 article-title: Enzalutamide: a Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.Ccr-12-2910 contributor: fullname: Hoffman-Censits – volume: 8 start-page: 1251 year: 2019 ident: B25 article-title: Comparison of Radiographic Progression-free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort publication-title: J. Clin. Med. doi: 10.3390/jcm8081251 contributor: fullname: Komura – volume: 8 start-page: 55 year: 2017 ident: B26 article-title: First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00055 contributor: fullname: Li – volume: 67 start-page: 53 year: 2015 ident: B17 article-title: Molecular Characterization of Enzalutamide-Treated Bone Metastatic Castration-Resistant Prostate Cancer publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.05.005 contributor: fullname: Efstathiou – volume: 19 start-page: 6383 year: 2011 ident: B23 article-title: Discovery of Orteronel (TAK-700), a Naphthylmethylimidazole Derivative, as a Highly Selective 17,20-lyase Inhibitor with Potential Utility in the Treatment of Prostate Cancer publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2011.08.066 contributor: fullname: Kaku – volume: 34 start-page: 200 year: 2017 ident: B33 article-title: Impact of Prior Androgen receptor-axis-targeted Agents on the Clinical Activity of Subsequent Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparative Assessment between Abiraterone Acetate and Enzalutamide publication-title: Med. Oncol. doi: 10.1007/s12032-017-1060-9 contributor: fullname: Miyake – volume: 93 start-page: 489 year: 1941 ident: B22 article-title: A New Society for X-Ray and Electron Diffraction Research Workers publication-title: Science doi: 10.1126/science.93.2421.489 contributor: fullname: Huggins – volume: 76 start-page: 1519 year: 2016 ident: B10 article-title: Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer after First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11) publication-title: Prostate doi: 10.1002/pros.23236 contributor: fullname: Cathomas – volume: 77 start-page: 639 year: 2017 ident: B13 article-title: Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison publication-title: Prostate doi: 10.1002/pros.23309 contributor: fullname: Chopra – volume: 23 start-page: 8253 year: 2005 ident: B40 article-title: Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling axis publication-title: J. Clin. Oncol. doi: 10.1200/jco.2005.03.4777 contributor: fullname: Scher – volume: 21 start-page: 131 year: 2019 ident: B27 article-title: Clinical Activity of Abiraterone Plus Prednisone in Docetaxel-Naοve and Docetaxel-Resistant Chinese Patients with Metastatic Castration-Resistant Prostate Cancer publication-title: Asian J. Androl. doi: 10.4103/aja.aja_85_18 contributor: fullname: Lin – volume: 371 start-page: 424 year: 2014 ident: B7 article-title: Enzalutamide in Metastatic Prostate Cancer before Chemotherapy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1405095 contributor: fullname: Beer – volume: 24 start-page: 1802 year: 2013 ident: B34 article-title: Clinical Activity of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Enzalutamide publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt138 contributor: fullname: Noonan – volume: 367 start-page: 1187 year: 2012 ident: B39 article-title: Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1207506 contributor: fullname: Scher – volume: 50 start-page: 78 year: 2014 ident: B8 article-title: Antitumour Activity of Enzalutamide (MDV3100) in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Pre-treated with Docetaxel and Abiraterone publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2013.08.020 contributor: fullname: Bianchini – volume: 368 start-page: 138 year: 2013 ident: B38 article-title: Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1209096 contributor: fullname: Ryan – volume: 66 start-page: 646 year: 2014 ident: B42 article-title: The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer publication-title: Eur. Urol. doi: 10.1016/j.eururo.2014.01.018 contributor: fullname: Schweizer |
SSID | ssj0000399364 |
Score | 2.3749394 |
SecondaryResourceType | review_article |
Snippet | To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or... Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or... Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or... |
SourceID | doaj pubmedcentral proquest crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 843110 |
SubjectTerms | abiraterone combined therapy docetaxel metastatic castration-resistant prostate cancer orteronel Pharmacology sequential therapy |
SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dSxwxEA_FJ1-KH62eHyWF4oPc6m2SzSV9KbYoUmgVVPAtTDYTFM49OU_w_OudbE69k4IvfQvZhQzzm2RmyMwvjH1DIzCKqi6wLkWhaFwYpaDoGSALCNiPMTUn__mrjy_U78vqcuapr1QTlumBs-L2wXolUYNCjcroCLrCPqV06aluL2Ju3SurmWSqPYOT39UqX2NSFmb34-0VJP5PIfYMOc3UMTvjiFq-_n8FmW9rJWecz9ES-ziNGvlBlnaZfcBmhe2cZtrpSZefv3ZR3XX5Dj99JaSerLKzA59u03E0bLDLT0Z5NOjyw-YRyPLg5joghyZwcjk4hgccfOdnbY017f8BH444HRuUQmOYrjT58YldHB2e_zoupo8pFLXS1ZgQ8DbqqIBUqS1YiIilVDLEUNugtQ-RYh0NFM_VAJ6-UKCBAFUg79Wjic9soSHh1hmX1ksZpQ0CAsEivEcUWtgY0ZoYZYftPmvW3WbODEe5RoLBtTC4BIPLMHTYz6T7lx8T3XU7QUbgpkbg3jOCDvv6jJyj7ZHuPKDB4f2dE1pqOkeFoIXWMpIvSyUm2NR722H9OYznZJn_0lxftRTcxtiyMr2N_yH8JltM-kil4GV_iy2MR_e4TZHO2H9pjfoJ2dP_bQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA-lvvgifntaJYL0QW7rXZLNbQQpVVqKUC20B30Lk82kLZx77d4Vev71zuzutZ7co28h2SXD_CbzQTIzQnzAQmFSeZlhOVSZoXFWGAPZoACSgIijlDg5-eiHPRyb72f52YZYtrfqGDhbG9pxP6lxPdm5vV7s0oH_whEn2dtP6eoCuLSnUjsF2UNOuHqgjDYs8Eedt98oZjbG1rR3m-v_XLFOTRH_dZ7nvw8o_7JIB4_Fo86VlHst9k_EBlZPxfZxW4t60Zen96lVs77clsf3VaoXz8TJXuArdqynFfblz7odTfpyv_oNJI7w6zKihCpKskM4h1ucfJYnzcNrUgoTOa0l6RKKqzF2Oy12n4vxwf7pt8Os67CQlcbmc4IluGSTAQsUJoODhDjURscUSxetDTGRA2SBnLwSINAKeR8IkEcyaQOaeCE2KyLulZDaBa2TdlFBNGhVCIjKKpcSuiIl3RMfl5z1V20hDU8BCMPgGxg8w-BbGHriK_P-7kOugd1MTOtz3x0pDy4YjUQ5WjSFTWBzHFGwz03cg0quJ94vkfN0ZvgiBCqc3sy8stqSclWKNnrZInm3FZeH5YTcnhitYLxCy-pKdXnR1OUuCjfMi8Hr_0H8G_GQ-cHvw4ejLbE5r2_wLbk_8_CuEeo_vacH4A priority: 102 providerName: Scholars Portal |
Title | Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35250590 https://search.proquest.com/docview/2636887220 https://pubmed.ncbi.nlm.nih.gov/PMC8891580 https://doaj.org/article/a9b43e6a4e6e486fa65e76909082b2f9 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdtn_Yy9r1sXdFg9GHE-ZBk2drL6EpLGWQLtIW-mZN1WgOJE9wUmv31O8l224w97cUIy0aHfmfdnXX3E2OfMBfoRVomWI5Foqid5EpBMsqBNMBh5n0oTp780GeX6vtVerXD0q4WJibtl3Y2qOaLQTW7jrmVq0U57PLEhtPJcZ6bcZqPhrtsN5PyUYgel99gcrVqdjApADNDv7qGQP0pxCAnezkOp78FFtBQd7lljiJr_79czb8zJh-ZoNNn7GnrO_KjRsbnbAerF-xw2pBPb_r84qGW6qbPD_n0gZZ685KdH9mwp471ssI-_1k3rXmfn1S_gfQPFjOHHCrHyfDgGu5w_oWfx0xrWgXmfFlzWjwokEbXjrT5-opdnp5cHJ8l7ZEKSal0uiYcrPHaK9BAcTEY8IhjqaTzrjROa-s8eTwayKsrASz1kLuBAKkjGzaiG6_ZXkXCvWVcGiull8YJcAq1sBZRaGG8R5N7L3vsczezxaphzigo4giIFBGRIiBSNIj02Lcw9_cPBtLreGNZ_ypa6AswVkkkyVGjyrUHnWJG0X04td0Kb3rsY4dcQR9J2PmACpe3N4XQUtNqKgQN9KZB8n6oThN6LNvCeEuW7R7Sy0jE3erhu_9-8z17EiYhZIGPs322t65v8QM5OWt7EH8O0HWi8oOo4H8AULEB6Q |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGeIAX7pdyNRLaA2rSxnHcmBc0pk0F1lFpHdqbZcfHrKJNqyyV6H49x7ls68QLvFlxIjs-n89FPuczIe8hZeBYkgWQRSzg2A5SznXQTzUiwMLAOV-cPDoSwxP-9TQ53SJJWwtTJe1nZhrms3mYT8-q3MrlPOu1eWK98WgvTWWUpP3eLXIb9ysbXAvSKwXsja7g9RkmhmCy55Zn2pN_MhamaDEjf_-b5wH1lZcbBqni7f-bs3kzZ_KaETq4T360069zT36Fq9KE2cUNZsd__r8H5F7jltLduvsh2YL8EdkZ17zW6y6dXJVpnXfpDh1fMV6vH5PjXeOP66FY5NCl34u6NevS_fxCI7T1fGqB6txStGlQ6t8w-0iPqyRuVDAzuigo6iWM0cE2I60_PSEnB_uTvWHQ3NYQZFwkJYrYSCcc10JjyK2ldgBRzGPrbCatEMY6dKaERocx09pgD3oyoHVi0Tz28cFTsp3j5J4TGksTxy6WlmnLQTBjAJhg0jmQqXNxh3xoRaaWNSmHwmDGi1pVolZe1KoWdYd89kK9fNHzaVcPFsVP1ay60tLwGHDmIICnwmmRwEDIvr8Q3jAnO-RdCwmF-88fqugcFqtzxUQsUFEzhgM9qyFyOVQLsQ4ZbIBnYy6bPQiJiuO7gcCL__7yLbkznIwO1eGXo28vyV2_ID7ZPBq8IttlsYLX6EuV5k21c_4Axk0iGQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbB2Mvu1_S3TQYfRixHcuyYu1ldF1Dd2kXaAulL0KyjtbQxAmuA0t__Y7suE3KnvomZBldziedc9DRdwj5CBkDx9I8gDxmAcdykHGug16mEQEW-s75x8n7B2LvmP84SU9WUn3VQfu5GYXFeBIWo7M6tnI2yaM2Tiwa7u9kmYzTrBfNrIvuknu4Z5lccdTrQ9grXsGbe0x0w2TkZmfaE4AyFmaoNWOfA85zgfrXl2tKqebu_5_BeTNuckURDR6R03YKTfzJeTivTJhf3mB3vNUcH5OHS_OUbjdNnpA7UDwlW8OG33rRpUfXz7UuunSLDq-ZrxfPyOG28df2UE4L6NLfZVMad-lucakR4noyskB1YSnqNqj0Xxh_pod1MDceNGM6LSmeT-irg132tPjynBwPdo929oJl1oYg5yKtUNRGOuG4Fhpdby21A4gTnlhnc2mFMNahUSU0Go651ga_oEUDWqcW1WQPK16QjQIH94rQRJokcYm0TFsOghkDwASTzoHMnEs65FMrNjVryDkUOjVe3KoWt_LiVo24O-SrF-xVQ8-rXVdMyz9qufJKS8MTwJGDAJ4Jp0UKfSF7PjG8YU52yIcWFgr3ob9c0QVM5xeKiUTggc0YdvSygclVVy3MOqS_BqC1sax_QVjUXN9LGGze-s_35P7w20D9-n7w8zV54NfDx5zH_Tdkoyrn8BZNqsq8qzfPP76KJJk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abiraterone%2C+Orteronel%2C+Enzalutamide+and+Docetaxel%3A+Sequential+or+Combined+Therapy%3F&rft.jtitle=Frontiers+in+pharmacology&rft.au=Ming-kun+Chen&rft.au=Ming-kun+Chen&rft.au=Zhi-jian+Liang&rft.au=Zhi-jian+Liang&rft.date=2022-02-17&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=13&rft_id=info:doi/10.3389%2Ffphar.2022.843110&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_a9b43e6a4e6e486fa65e76909082b2f9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |